Acharya Prativa, Gautam Adhikari Pragati, Kharel Sitaula Ranju, Thapa Madhu
Department of Ophthalmology, Institute of Medicine, Tribhuvan University, B.P Koirala Lions Centre For Ophthalmic Studies, Kathmandu, Nepal.
BMC Ophthalmol. 2025 Sep 9;25(1):500. doi: 10.1186/s12886-025-04247-w.
To evaluate the ganglion cell complex thickness in patients taking oral hydroxychloroquine.
In this hospital-based, cross-sectional, non-interventional, comparative study, 87 eyes of 87 patients taking hydroxychloroquine were recruited. All the patients underwent complete ophthalmological evaluation along with dilated fundus examination. Patients were divided into two groups based on the duration of hydroxychloroquine intake: Group 1 (62 patients having duration of hydroxychloroquine intake < 5 years) and Group 2 (25 patients having duration of hydroxychloroquine intake ≥ 5 years). Age and gender-matched healthy volunteers with normal ocular findings were taken as controls. Average, superior, inferior GCC thickness, focal loss volume, and global loss volume were measured by RTvue XR Avanti SD-OCT.
The average, superior, and inferior GCC thicknesses were significantly reduced in both Group 1 (< 5 years) and Group 2 (≥ 5 years) as compared to controls (p < 0.001). In Group 1, mean GCC values were 94.70 ± 6.34 μm (average), 94.43 ± 6.28 μm (superior), and 94.74 ± 6.81 μm (inferior), while the corresponding values in controls were 99.79 ± 4.61 μm, 99.38 ± 4.63 μm, and 99.97 ± 4.61 μm. Likewise, FLV and GLV in Group 1 were 1.76 ± 2.5% and 4.07 ± 3.27%, significantly higher than in controls (0.72 ± 0.45% and 1.39 ± 1.1%, respectively; p = 0.002 for FLV, p = 0.001 for GLV). Similarly, in Group 2, mean GCC thicknesses were 92.70 ± 6.39 μm (average), 92.44 ± 5.92 μm (superior), and 93.32 ± 7.25 μm (inferior), all significantly lower than in controls (p < 0.001). While GLV was significantly elevated in Group 2 (4.46 ± 4.42%; p-0.003), the difference in FLV (1.23 ± 1.12%) was not statistically significant compared to controls (p-0.077).
The Ganglion Cell Complex thickness was significantly thinner in patients taking hydroxychloroquine along with elevated Focal Loss Volume % and Global Loss Volume %. However, no statistically significant correlation was observed between GCC thickness and duration of hydroxychloroquine use.
评估服用口服羟氯喹的患者的神经节细胞复合体厚度。
在这项基于医院的横断面、非干预性、对比研究中,招募了87例服用羟氯喹的患者的87只眼睛。所有患者均接受了全面的眼科评估以及散瞳眼底检查。根据羟氯喹的服用时长将患者分为两组:第1组(62例服用羟氯喹时长<5年)和第2组(25例服用羟氯喹时长≥5年)。将年龄和性别匹配且眼部检查结果正常的健康志愿者作为对照。通过RTvue XR Avanti SD-OCT测量平均、上方、下方神经节细胞复合体厚度、局灶性损失体积和整体损失体积。
与对照组相比,第1组(<5年)和第2组(≥5年)的平均、上方和下方神经节细胞复合体厚度均显著降低(p<0.001)。在第1组中,神经节细胞复合体的平均厚度值分别为94.70±6.34μm(平均)、94.43±6.28μm(上方)和94.74±6.81μm(下方),而对照组的相应值分别为99.79±4.61μm、99.38±4.63μm和99.97±4.61μm。同样,第1组的局灶性损失体积和整体损失体积分别为1.76±2.5%和4.07±3.27%,显著高于对照组(分别为0.72±0.45%和1.39±1.1%;局灶性损失体积p=0.002,整体损失体积p=0.001)。类似地,在第2组中,神经节细胞复合体的平均厚度分别为92.70±6.39μm(平均)、92.44±5.92μm(上方)和93.32±7.25μm(下方),均显著低于对照组(p<0.001)。虽然第2组的整体损失体积显著升高(4.46±4.42%;p=0.003),但与对照组相比,局灶性损失体积的差异(1.23±1.12%)无统计学意义(p=0.077)。
服用羟氯喹的患者神经节细胞复合体厚度显著变薄,同时局灶性损失体积百分比和整体损失体积百分比升高。然而,未观察到神经节细胞复合体厚度与羟氯喹使用时长之间存在统计学上的显著相关性。